SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-066608
Filing Date
2024-05-30
Accepted
2024-05-30 16:15:12
Documents
12
Period of Report
2024-05-29
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20240529.htm   iXBRL 8-K 45220
2 EX-3.1 cadl-ex3_1.htm EX-3.1 13904
  Complete submission text file 0000950170-24-066608.txt   184945

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20240529.xsd EX-101.SCH 29262
15 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20240529_htm.xml XML 5065
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 241005594
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)